With confirmed central nervous system penetration and strong suppression of a key inflammatory signal, the data have prompted BioAge to expand the trial to include participants with obesity and elevated inflammation.<\/p>\n
The company\u2019s goal is ambitious: to address a core biological driver of cardiometabolic disease that existing treatments, including widely used GLP-1 drugs, may not fully reach.<\/p>\n
\u201cWe\u2019re very encouraged by the interim data from our ongoing Phase 1 trial of BGE-102, an NLRP3 inhibitor with best-in-class potential,\u201d said Dr Kristen Fortney, BioAge\u2019s CEO and co-founder. \u201cOnce-daily doses of 60 mg and above were well tolerated and exceeded target IC90 levels in both the periphery and the brain.\u201d<\/p>\n
![\"Food](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2025\/12\/Dr-Kristen-Fortney_-co-founder-and-CEO-of-BioAge-Labs-scaled-1-1024x650.jpg\")
Dr Kristen Fortney<\/p>\n
NLRP3 is a key molecular switch that drives inflammation throughout the body. When overactive, it contributes to a wide range of diseases, including obesity-related cardiovascular risk, neurodegenerative disorders and metabolic dysfunction.\u00a0<\/p>\n
One of the most important signals downstream of NLRP3 is IL-1\u03b2, a cytokine that triggers the production of CRP, a clinically validated biomarker of cardiovascular risk.<\/p>\n
Reaching the brain has been a major challenge for NLRP3 inhibitors. BGE-102\u2019s ability to exceed target IC90 concentrations in cerebrospinal fluid, especially at doses above 60 mg, positions it as one of the few drugs in this category that may simultaneously address inflammation in both the brain and peripheral tissues.<\/p>\n
This dual action could be meaningful for patients with obesity, who often exhibit elevated systemic inflammation that contributes to long-term cardiac and metabolic complications.<\/p>\n
In the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, BGE-102 was well tolerated at all doses tested \u2013 up to 120 mg. Side effects were mild to moderate and resolved without intervention. Researchers also observed clear dose proportionality, meaning the drug\u2019s exposure levels scale reliably with dosage.<\/p>\n
Importantly, BGE-102 achieved between 90% and 98% suppression of IL-1\u03b2 after 14 days. This finding suggests strong biological activity and reinforces the potential for downstream reductions in inflammatory markers such as hsCRP.<\/p>\n
\u201cIn recent clinical experience, NLRP3 inhibitors can achieve substantial reductions in inflammatory biomarkers such as hsCRP within the first week of treatment,\u201d said Dr Paul Rubin, Chief Medical Officer of BioAge.\u00a0<\/p>\n
\u201cBecause IL-1\u03b2 is a key upstream regulator of CRP production, the potent and sustained IL-1\u03b2 suppression we observed with BGE-102 has the potential to translate directly into meaningful effects on hsCRP,\u201d he added.<\/p>\n
The broader market has already shown interest in NLRP3 inhibition. Ventyx\u2019s Phase 2 data earlier this year demonstrated a 78% reduction in hsCRP in patients with obesity and cardiovascular risk.\u00a0<\/p>\n
The announcement nearly doubled the company\u2019s stock and triggered negotiations with Sanofi, which had previously secured a $27 million right-of-first-negotiation deal for the program.<\/p>\n
BioAge\u2019s differentiator lies in its drug\u2019s brain penetration and its discovery platform, which uses large datasets from human aging cohorts to identify molecular targets linked to longevity and resilience. That platform flagged NLRP3 as a driver of chronic inflammation, a biological thread that connects metabolic aging, cardiovascular disease, and neurological decline.<\/p>\n
The Phase 1 trial has now expanded to include obese participants with elevated hsCRP, offering a crucial opportunity to test whether BGE-102 can meaningfully reduce inflammatory biomarkers in individuals most likely to benefit. BioAge expects to complete these MAD cohorts in the first half of 2026.<\/p>\n
BioAge also plans to launch a Phase 2a proof-of-concept trial next year. This study will enroll approximately 100 participants with obesity and cardiovascular risk, and will test 12 weeks of BGE-102 monotherapy against placebo.\u00a0<\/p>\n
The primary endpoint will be the percent change in hsCRP, with secondary endpoints including metabolic and inflammatory biomarkers and MRI imaging. If successful, the trial could position BGE-102 as a meaningful complement \u2013 or alternative \u2013 to GLP-1 medications, particularly for patients whose cardiometabolic risk is tied to inflammation rather than appetite or weight alone.<\/p>\n
Photographs courtesy of BioAge<\/p>\n